BioSpace News Archive

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that the Company granted an aggregate of 9,500 restricted stock units to three newly-hired employees.

Akebia Therapeutics, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 4 newly-hired employees options to purchase an aggregate of 76,000 shares of Akebia’s common stock on May 31, 2024, as inducements material to such employee entering into employment with Akebia.

Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced encouraging data from its Phase 1 DRAGON proof-of-concept trial of SRK-181, a selective inhibitor of latent TGFβ1 activation, in combination with pembrolizumab in patients with advanced solid tumors.

Avance Clinical, the award-winning Australian and North American market-leading CRO for biotechs, has signed a Memorandum of Understanding (MOU) with Julius Clinical, a leading CNS

Crinetics Pharmaceuticals, Inc. announced initial findings from the development program of its second clinical product candidate, atumelnant*, a novel, once-daily oral adrenocorticotropic hormone receptor antagonist.

Aurigene Pharmaceutical Services Limited (“Aurigene”), a Dr. Reddy’s Laboratories Limited company, inaugurated its biologics facility spread across 70,000 sq.ft. in Genome Valley

City of Hope®, one of the largest cancer research and treatment organizations in the United States, announced that effective June 10, Angelique L. Richard, Ph.D., R.N., will be chief operating officer of City of Hope National Medical Center, City of Hope Los Angeles, City of Hope Orange County and City of Hope’s Southern California clinical network.

Mythic Therapeutics today announced initial dose escalation results from its ongoing Phase 1 KisMET-01 study evaluating its investigational cMET-targeting ADC, MYTX-011, in patients with previously treated, locally advanced or metastatic non-small cell lung cancer (NSCLC) at the American Society of Clinical Oncology (ASCO) Annual Meeting.

ADC Therapeutics SA (NYSE: ADCT) today announced that the Company has made grants of options to purchase an aggregate of 109,800 of the Company’s common shares to three new employees on June 3, 2024 (each, a “Grant”).

BridgeBio Pharma, Inc. today announced that members of its management team, along with Ravi Savarirayan, M.D., Ph.D., of Murdoch Children’s Research Institute in Melbourne, Australia, and the global lead investigator for PROPEL 2, will host a call on June 4, 2024, at 8:00 am ET.